Global Metastatic Bone Cancer Market Insights Forecasts to 2032
- The Global Metastatic Bone Cancer Market Size was valued at USD 19.7 Billion in 2022.
- The market is growing at a CAGR of 7.04% from 2022 to 2032.
- The worldwide Metastatic Bone Cancer Market size is expected to reach USD 38.9 Billion by 2032.
- Europe is expected to grow the fastest during the forecast period.
Get more details on this report -
The Global Metastatic Bone Cancer Market Size is expected to reach USD 38.9 Billion by 2032, at a CAGR of 7.04% during the forecast period 2022 to 2032.
When cancerous cells from other parts of the body affect the bone, it is termed bone metastasis. Metastatic Bone Disease and secondary bone malignancy are different names for bone metastasis. Almost all malignancies have the potential to spread to the bone. However, some malignancies, such as breast and prostate cancer, quickly spread to the bones. People who receive a cancer diagnosis early in life are more likely to develop bone metastases. Additionally, bone metastasis is more likely to occur in cancer patients at an advanced stage of the disease. In the spine, pelvis, and thigh, bone metastasis frequently occurs. In addition to developing after cancer therapy, bone metastatic can be the earliest symptom of the disease. Bone pain, shattered bones, weakness, and elevated calcium levels in the blood that cause nausea, vomiting, constipation, and disorientation are just a few of the signs of bone metastases. Also, present are some of the symptoms, such as bowel and urine incontinence. The Modern Medicine Network reports that between 30% and 60% of individuals with advanced lung cancer get bone metastases. Treatment for bone metastasis is rarely therapeutic, however, by using systemic anticancer drugs in the context of multimodal supportive care, disease management is typically possible for several years. To lessen the impact of metastatic bone disease on bodily functions, this care involves the use of local treatments like radiation therapy, orthopedic surgery, and specialized palliative care, as well as bone-targeted medications like bisphosphonates or denosumab to inhibit tumor-associated osteolysis and prevent skeletal morbidity.
This research report categorizes the global metastatic bone cancer market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global metastatic bone cancer market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global metastatic bone cancer market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.
Global Metastatic Bone Cancer Market Report Coverage
|Market Size in 2022:||USD 19.7 Billion|
|Forecast Period:||2022 - 2032|
|Forecast Period 2022 - 2032 CAGR:||7.04%|
|2032 Value Projection:||USD 38.9 Billion|
|Historical Data for:||2018 - 2021|
|No. of Pages:||210|
|Tables, Charts & Figures:||135|
|Segments covered:||By Cancer Type, By Diagnosis, By Therapy, By Region|
|Companies Covered:||Merck, Amgen, F. Hoffmann-La Roche, Eli Lilly and Company, Novartis, Bayer, Fresenius Kabi, Boston Scientific Corporation, Medtronic, C. R. Bard|
Get more details on this report -
The market for metastatic bone disease is projected to expand rapidly due to rising healthcare costs and an aging population. The Global Metastatic Bone Disease Market is driven by an increase in the incidence of cancer worldwide, favorable reimbursement conditions, strict regulatory policies ensuring better product quality, an increase in the funding of cancer research, and the approval of new drugs. Also, an increase in cancer awareness campaigns by governments and patient support organizations may drive market growth during the forecast period. Moreover, during the period covered by the projection, the market for bone metastatic bone disease would see growth due to expanding technical developments, new product development, and clinical trial. In addition, During the projected period, the market is anticipated to be driven by improvements in hospital infrastructure in developed economies like North America and Europe and an increase in medical tourism in Asia Pacific.
The Food and Drug Administration's (FDA) delayed medication clearance process and the high cost of cancer therapy are the main factors limiting the growth of the bone metastasis industry. Additionally, the market revenue development of bone metastasis is restricted by the lack of diagnostic methods.
- In 2022 the osteoblastic bone metastasis segment is influencing the market with the largest market share during the forecast period.
Based on the cancer type, the global metastatic bone cancer market is segmented into osteoblastic bone metastasis and osteolytic bone metastasis. Among these segments, the osteoblastic bone metastasis segment is dominating the market with the largest revenue share during the forecast period owing to Women with underlying breast cancer often developing osteoblastic bone metastases. During the projected period, it is expected that the high prevalence of breast cancer relative to other cancer types will contribute to the segment's leading share. Although the presence of a localized bone-formation response, the primary lesion is lytic and destructive. Osteolytic metastases are a possibility in solid tumors such as breast, prostate, thyroid, lung, and kidney cancer. In addition, substantial bone loss is another prevalent side effect of multiple myeloma.
- In 2022, the biopsy segment is dominating the largest market growth over the forecast period.
Based on the diagnosis, the global metastatic bone cancer market is classified into biopsy, blood test, imaging, & others. Throughout these segments, the biopsy segment is dominating the market. A bone biopsy is a procedure in which bone samples are taken and examined for the presence of cancer or other abnormal cells (either during surgery or with a special biopsy needle). The outer layers of the bone are sampled during a bone biopsy, as opposed to a bone marrow biopsy, which uses the core portion of the bone. Furthermore, Imaging tests are carried out to investigate any symptoms or signs that could indicate bone metastases. There are a variety of tests that may be performed, including X-rays, bone scans, CT scans, and MRIs.
- In 2022, the chemotherapy segment is leading the largest market share during the forecast period.
On the basis of therapy, the global metastatic bone cancer market is divided into chemotherapy, hormone therapy, targeted therapy, immunotherapy, and radiopharmaceuticals. Among these segments, the osteoblastic bone metastasis segment is dominating the market with the largest share during the forecast period due to It involves the use of drugs to kill or slow down the growth of cancer cells. Chemotherapy can be administered systemically (intravenously or orally) and is effective in targeting cancer cells throughout the body, including those that have spread to the bones.
Regional Segment Analysis of the metastatic bone cancer market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America dominates the market with the largest market share during the forecast period
Get more details on this report -
North America is dominating the significant market growth during the forecast period because the region has a robust healthcare industry and breast cancer is becoming more common there. The region has seen an increase in cancer incidence as a result of consuming more highly processed foods, sugary beverages, becoming obese, developing Type 2 diabetes, living a sedentary lifestyle, and drinking more alcohol. The market demand is predicted to increase with more research being done on cancer stem cells. The presence of large firms like Merck & Co., Inc., and Pfizer, Inc. also contributes to the regional market's growth. In addition, the producers in the area are developing fresh, cutting-edge goods for the bone metastases market. As a result, growing strategic alliances, higher R&D for new product launches, and rising incidence rates of bone metastasis illnesses are the primary drivers boosting the demand for the bone metastatic market over the projection period.
Europe is predicted to be the second fastest-growing region during the forecast period
Europe is expected to grow at the highest growth rate over the forecast period due to the rising prevalence of prostate cancer, local government assistance, and insurance reimbursement practices. Prostate cancer is the most prevalent disease in men, with over 47,200 new cases reported each year, according to Cancer Research U.K. In the UK, 26% of all new cancer cases in men are prostate cancer. Over the projection period, early adoption of cutting-edge medical technology for cancer diagnostics and high cancer awareness are expected to support the region's market growth.
The report offers the appropriate analysis of the key organizations/companies involved within the global metastatic bone cancer market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- F. Hoffmann-La Roche
- Eli Lilly and Company
- Fresenius Kabi
- Boston Scientific Corporation
- C. R. Bard
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
- In March 2022, the first targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer, Novartis Pluvicto, was given FDA approval.
- In June 2021, 177Lu-PSMA-617, a targeted radioligand therapy, along with the best standard of care (SOC) was compared to the SOC alone in the Phase III VISION study, and the results showed a significant improvement in overall survival (OS) in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.
This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the Global Metastatic Bone Cancer Market based on the below-mentioned segments:
Global Metastatic Bone Cancer Market, By Cancer Type
- Osteoblastic Bone Metastasis
- Osteolytic Bone Metastasis
Global Metastatic Bone Cancer Market, By Diagnosis
- Blood Test
Global Metastatic Bone Cancer Market, By Therapy
- Hormone Therapy
- Targeted Therapy
Metastatic Bone Cancer Market, By Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
Need help to buy this report?